Ki Tae Yoon

Ki Tae Yoon

Auto-generated profile, based on publicly available information

Ki Tae Yoon

Department of Internal Medicine, Pusan National University College of Medicine, Yangsan, Korea

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2021 in Current Opinion in Gastroenterology
Verified
Journal Article
Closed access
HLHongqun Liu
Hongqun Liu
KYKi Tae Yoon
Ki Tae Yoon
JZJing Zhang
Jing Zhang
SLSamuel Lee
Samuel Lee
Purpose of review: Cirrhotic cardiomyopathy (CCM) is a well-recognized entity. When patients with CCM encounter challenges such as liver transplantation, overt cardiac dysfunction manifests, leading to morbidity and mortality. Although revised diagnostic criteria for CCM have recently been proposed, these still need to be validated. Recent findings: Previous reviews have summarized the mechanisms of CCM, such as abnormalities of the β-adrenergic pathway, cardiac plasma membrane biophysical and biochemical properties, and electrophysiological changes. Cardiomyocyte apoptosis, inflammation, and oxidative stress also play important roles. The present review details further mechanisms of CCM, which include myosin heavy chain isoform shifts and abnormalities in cellular calcium transients. Additionally, we review recent studies on therapeutic strategies. Recent work underscores the importance of CCM in the natural history of the immediate and medium-term postoperative period after liver transplantation. Appropriate management strategies for CCM remain the area of greatest unmet need, requiring much further research. Summary: CCM is a clinically relevant syndrome affecting patients with cirrhosis, leading to increased morbidity and mortality. New diagnostic criteria have been recently proposed by an expert working group. The pathogenic mechanisms remain incompletely clarified and optimal management strategies need much further study.

1 January 2021 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
JLJae Seung Lee
Jae Seung Lee
YCYoung Eun Chon
Young Eun Chon
BKBeom Kyung Kim
Beom Kyung Kim
JPJun Yong Park
Jun Yong Park
Do Young KimDo Young Kim
Do Young Kim
TGThe Korean TACE Study Group
The Korean TACE Study Group
Lee JS, et al. Yonsei Med J. 2021 Jan;62(1):12-20. https://doi.org/10.3349/ymj.2021.62.1.12

17 April 2012 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
HWHyun Young Woo
Hyun Young Woo
Jeong HeoJeong Heo
Jeong Heo
KYKi Tae Yoon
Ki Tae Yoon
Gwang Ha KimGwang Ha Kim
Gwang Ha Kim
DKDae-Hwan Kang
Dae-Hwan Kang
MCMong Cho
Mong Cho
Sorafenib has been shown to improve survival of patients with advanced hepatocellular carcinoma (HCC). However, its tolerance in clinical practice has not been well evaluated, and whether sorafenib should be continued in cases of tumor progression or intolerance has not been established. The authors retrospectively assessed sorafenib tolerability, and evaluated the clinical course in patients who showed progression during sorafenib treatment. Between March 2008 and July 2010, 80 patients with advanced HCC were treated with sorafenib. With a median of 78.5 days of treatment, 15% discontinued sorafenib due to adverse events. The duration was significantly longer in patients with Child-Pugh class A liver function (233 ± 240 days) than in those with Child-Pugh class B (100 ± 136 days; p = 0.006). The overall progression rate was 53% (43/80), with a median time to progression of 105 days (95% confidence interval, 59-150 days). After progression, 14 patients received conservative care only (group 1), 14 continued sorafenib monotherapy (group 2), 6 changed to treatment without sorafenib (group 3) and 9 underwent additional treatment with concomitant sorafenib (group 4). Survival after progression was significantly better in groups 2, 3 and 4 than in group 1 (p = 0.001). Sorafenib was tolerable for most patients in clinical practice and may be continued in patients who show progression during sorafenib therapy. However, it was less well tolerated in patients with Child-Pugh class B liver function and should be used with caution in these patients.

1 June 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
HLHye Won Lee
Hye Won Lee
JPJun Yong Park
Jun Yong Park
JLJin Woo Lee
Jin Woo Lee
KYKi Tae Yoon
Ki Tae Yoon
CKChang Wook Kim
Chang Wook Kim
SASang Hoon Ahn
Sang Hoon Ahn

24 October 2011 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
PDF file
JLJae-Hyeok Lee
Jae-Hyeok Lee
TYTae-Il Yang
Tae-Il Yang
MCMong Cho
Mong Cho
KYKi-Tae Yoon
Ki-Tae Yoon
SBSeung-Kug Baik
Seung-Kug Baik
YHYong-Hee Han
Yong-Hee Han

1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YHYoung Mi Hong
Young Mi Hong
KYKi Tae Yoon
Ki Tae Yoon
Jeong HeoJeong Heo
Jeong Heo
HWHyun Young Woo
Hyun Young Woo
WLWon Lim
Won Lim
MCMong Cho
Mong Cho
Hong YM, et al. J Korean Med Sci. 2016 Oct;31(10):1604-1610. https://doi.org/10.3346/jkms.2016.31.10.1604